title: Pharmacology of Alzheimer's disease: appraisal and prospects.
abstract: Ten years after the introduction of the first drug, tacrine, in the treatment of Alzheimer's disease, it seems appropriate to re-appraise the pharmacological processes of innovation in the research field of dementia. The aim of this review is to pinpoint concrete improvements achieved in this field, regarding experimental methods and clinical evaluation of the compounds, as well as the neurochemistry of the disease and cellular targets to consider in priority. This review deals with this objective in three parts: (1) assessment of current therapeutics, (2) discussion of the experimental models and clinical practices and (3) prospective drugs of the future. The implementation of considered strategies will require the involvement and close cooperation between political decisions, pharmaceutical companies and the scientific community.
authors.affiliation: Hôpital Universitaire, Strasbourg, France.
authors.forename: François
authors.initials: F
authors.lastname: Sellal
authors.forename: André
authors.initials: A
authors.lastname: Nieoullon
authors.forename: Géraldine
authors.initials: G
authors.lastname: Michel
authors.forename: Bernard François
authors.initials: BF
authors.lastname: Michel
authors.forename: Lucette
authors.initials: L
authors.lastname: Lacomblez
authors.forename: Hugo
authors.initials: H
authors.lastname: Geerts
authors.forename: Alexandra
authors.initials: A
authors.lastname: Delini Stula
authors.forename: Régis
authors.initials: R
authors.lastname: Bordet
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
authors.forename: Hervé
authors.initials: H
authors.lastname: Allain
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*
chemical_list: D018697:Nootropic Agents